Optiscan

Optiscan Imaging Limited
Appendix 4E
Preliminary final report

1. Company details

Name of entity:	Optiscan Imaging Limited
ABN:	81 077 771 987
Reporting period:	For the year ended 30 June 2026
Previous period:	For the year ended 30 June 2025

2. Results for announcement to the market

				$
Revenues from ordinary activities	down	-52.9%	to	448,769
Loss from ordinary activities after tax attributable to the owners of Optiscan Imaging Limited	up	10.7%	to	(6,986,043)
Loss for the year attributable to the owners of Optiscan Imaging Limited	up	10.7%	to	(6,986,043)

Dividends
There were no dividends paid or declared during the current financial period.

Comments
The loss for the consolidated entity after providing for income tax amounted to $6,986,043 (30 June 2025: $6,311,952).

Financial performance

During the financial year ending 30 June 2026 (FY26), the consolidated entity generated ordinary revenue of $448,769 from sales, system rentals and the provision of services, compared to $951,948 in the previous corresponding period. The 53% decrease in sales revenue was due to lower orders from Carl Zeiss Meditec (CZM) and lower sales of ViewnVivo.

Other income generated for the financial year was $3,711,078 (2025: $3,106,879). The Company recorded research and development incentive income of $2,398,465 (2025: $2,410,376), near similar elevated levels to last year due to the multiple R&D projects running in parallel and increased clinical study activities. The gastrointestinal flexible endomicroscope project associated with the CRC-P grant also progressed, resulting in grant payments received of $766,196 (2025: $361,907).

Further investment in commercial and R&D activity for the financial period increased total expenses for FY26 to $11,133,244 (2025: $10,350,445). With higher investment in R&D over the year to achieve production-ready medical devices for regulatory submissions, the Company has continued to refine the three microscopic medical devices revealed (InForm™ for pathology, InVue™ for surgery and InSpecta™ for veterinary medicine) for use across multiple clinical studies. There was also increased business activities through strategic conference engagement, commercial initiatives, and adding capabilities to the team to deliver on the strategy that will advance clinical validation and commercial readiness.

The net operating cash outflow for FY26 was $7,103,837 compared to $6,212,032 for the previous financial year. This higher cash outflow is due to increased R&D, clinical and commercial activities as outlined above.

Financial position

The net assets increased by $11,232,958 to $18,944,972 at 30 June 2026 (30 June 2025: $7,712,014). The working capital position of the consolidated entity as at 30 June 2026 resulted in an excess of current assets over current liabilities of $18,501,835 (30 June 2025: $7,354,694).

The increase in net asset position was due to increase in cash and cash equivalents following the capital raise completed on 23 September 2025 through its fully underwritten pro-rata renounceable entitlement offer that raised $17,751,045 with 208,835,829 shares issued.

3. Net tangible assets

	Reporting period Cents	Previous period Cents
Net tangible assets per ordinary security	1.82	0.92

The net tangible assets per ordinary security has been calculated excluding the Right-of-use asset amount and Intangibles.

4. Control gained over entities

Not applicable.

5. Loss of control over entities

Not applicable.

6. Dividends

Current period
There were no dividends paid or declared during the current financial period.

Previous period
There were no dividends paid or declared during the previous financial period.

7. Dividend reinvestment plans

Not applicable.

8. Details of associates and joint venture entities

Not applicable.

---

9. Foreign entities

Details of origin of accounting standards used in compiling the report:

Not applicable.

---

10. Audit qualification or review

Details of audit/review dispute or qualification (if any):

The financial statements have been audited and an unmodified opinion has been issued.

---

11. Attachments

Details of attachments (if any):

See the Optiscan Imaging Limited Annual Report for the period ended 30 June 2026 for further information.

---

12. Signed

Signed ______________________ Date: 25 August 2026

Robert Cooke
Non-executive Chairman